1
|
Gray B, Lubbock K, Love C, Ryder E, Hudson S, Scarth J. Analytical advances in horseracing medication and doping control from 2018 to 2023. Drug Test Anal 2024. [PMID: 39010718 DOI: 10.1002/dta.3760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 06/07/2024] [Accepted: 06/20/2024] [Indexed: 07/17/2024]
Abstract
The analytical approaches taken by laboratories to implement robust and efficient regulation of horseracing medication and doping control are complex and constantly evolving. Each laboratory's approach will be dictated by differences in regulatory, economic and scientific drivers specific to their local environment. However, in general, laboratories will all be undertaking developments and improvements to their screening strategies in order to meet new and emerging threats as well as provide improved service to their customers. In this paper, the published analytical advances in horseracing medication and doping control since the 22nd International Conference of Racing Analysts and Veterinarians will be reviewed. Due to the unprecedented impact of COVID-19 on the worldwide economy, the normal 2-year period of this review was extended to over 5 years. As such, there was considerable ground to cover, resulting in an increase in the number of relevant publications included from 107 to 307. Major trends in publications will be summarised and possible future directions highlighted. This will cover developments in the detection of 'small' and 'large' molecule drugs, sample preparation procedures and the use of alternative matrices, instrumental advances/applications, drug metabolism and pharmacokinetics, the detection and prevalence of 'endogenous' compounds and biomarker and OMICs approaches. Particular emphasis will be given to research into the potential threat of gene doping, which is a significant area of new and continued research for many laboratories. Furthermore, developments in analytical instrumentation relevant to equine medication and doping control will be discussed.
Collapse
|
2
|
Straub HM, Tully TN, Dirikolu L, Lehner AF, Zyskowski J, Buchweitz J. Pharmacokinetics of Trazodone in Hispaniolan Parrots ( Amazona ventralis). J Avian Med Surg 2024; 38:98-107. [PMID: 38980819 DOI: 10.1647/avianms-d-23-00047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2024]
Abstract
The objective of this study was to establish the pharmacokinetics of a single oral dose of trazodone in the Hispaniolan Amazon parrot (Amazona ventralis). Trazodone is a selective serotonin antagonist and reuptake inhibitor used commonly in both human and veterinary medicine as an antidepressant behavioral modification medicine. A single oral dose of compounded trazodone hydrochloride solution (20 mg/mL) at 50 mg/kg was administered to a total of 7 healthy adult Hispaniolan Amazon parrots. The 7 healthy adult parrots ranged in age from 10 to 15 years and weighed 228 to 323g. Blood was collected at baseline (2 weeks before study) and at 1, 2, 4, 6, 10, and 14 hours post-drug administration. Plasma concentrations of both trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) were measured via liquid chromatography tandem mass spectrometry. Noncompartmental pharmacokinetic analysis was completed. The half-life (t1/2) ± SD of trazodone for the Hispaniolan parrots was 1.89 ± 0.49 hours, and the t1/2 ± SD of mCPP metabolite was 1.9 ± 0.55 hours. Maximum serum drug concentrations, or Cmax (ng/mL), were 738.3 ± 285.3 for trazodone. Times to achieve Cmax (hours) for trazadone and the mCPP metabolite were 1 hour and 2 hours postdosing, respectively. While this study did not establish the behavioral effects of trazodone, no adverse side effects were observed throughout the 48-hour period following drug administration and blood collection. Our results indicate that the oral administration of a 50-mg/kg single dose of trazodone to Hispaniolan parrots may be considered a safe dose. Plasma concentrations are comparable to previously published values in humans, dogs, horses, and pigeons (Columba livia domestica) for up to 14 hours following dosing. This study indicates that further studies are needed to establish the pharmacodynamics and the efficacy of trazodone in the medical management of behavioral problems in psittacine species.
Collapse
Affiliation(s)
- Haley M Straub
- Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA,
| | - Thomas N Tully
- Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Levent Dirikolu
- Department of Comparative Biological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Andreas F Lehner
- Veterinary Diagnostic Laboratory, Section of Toxicology, Michigan State University, Lansing, MI 48910, USA
| | - Justin Zyskowski
- Veterinary Diagnostic Laboratory, Section of Toxicology, Michigan State University, Lansing, MI 48910, USA
| | - John Buchweitz
- Veterinary Diagnostic Laboratory, Section of Toxicology, Michigan State University, Lansing, MI 48910, USA
| |
Collapse
|
3
|
Hovda LR. Therapeutic Medications and Illicit Medications and Supplements. Vet Clin North Am Equine Pract 2024; 40:151-160. [PMID: 37951813 DOI: 10.1016/j.cveq.2023.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023] Open
Abstract
This article provides information on the toxicity of some therapeutic drugs, illicit drugs, and supplements. Medications in the therapeutic section are grouped into antibiotics, antipsychotic agents, bronchodilators, nonsteroidal anti-inflammatory drugs, opioids, and sedatives/tranquilizers. The section on illicit drugs and supplements provides information on more specific medications including commonly used or abused human medications and a few that are available only from Internet compounding pharmacies. Many drugs and supplements can be either therapeutic or illicit depending on the dosage and ultimate use of the horse. Some medications, however, are illicit no matter when and how they are administered.
Collapse
Affiliation(s)
- Lynn Rolland Hovda
- Safetycall International and Pet Poison Helpline, 3600 American Boulevard West, Suite 725, Bloomington, MN 55431, USA; Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA.
| |
Collapse
|
4
|
Hobbs K, Luethy D, Davis J, Mallicote M, Torcivia C, Kulp J, Stefanovski D, Futterman C, Cooper F, van Eps A. The effects of orally administered trazodone on ambulation and recumbency in healthy horses. J Vet Intern Med 2023; 37:1899-1906. [PMID: 37489582 PMCID: PMC10472990 DOI: 10.1111/jvim.16821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 07/07/2023] [Indexed: 07/26/2023] Open
Abstract
BACKGROUND Trazodone, a serotonin receptor antagonist and reuptake inhibitor, might be a useful adjunctive treatment in the initial management of horses with acute laminitis if it minimizes ambulation or encourages recumbency. OBJECTIVES (1) Evaluate the effects of PO trazodone on ambulatory activity and recumbency in healthy horses; and (2) assess the pharmacokinetics of multiple PO doses of trazodone. ANIMALS/METHODS In a randomized cross-over design, 8 healthy horses received placebo or trazodone at 2 doses (2.5 and 7.5 mg/kg) PO q12h for 48 hours with a 14-day washout period between treatments. Forelimb step frequency was measured using a hoof-mounted accelerometer and continuous video monitoring was used to detect recumbency. Groups were compared using repeated measures analysis of variance with Tukey's post hoc test. Trazodone and m-chlorophenylpiperazine (m-CPP) plasma concentrations were determined by ultra-high performance liquid chromatography-tandem mass spectrometry and pharmacokinetics were analyzed using noncompartmental methods. RESULTS Step frequency was lower in horses receiving 7.5 mg/kg trazodone than in the control group (mean step reduction: 44% ± 11%). Steps-area under the curve were significantly lower in the 7.5 mg/kg group (mean ± SD: 3375 ± 525 steps × hour) as compared to the 2.5 mg/kg group (mean ± SD: 5901 ± 2232; P = .02) and compared to control (mean ± SD: 6590 ± 1241; P = .001). No difference was found in the number of recumbent episodes (P = .92) or total duration of recumbency (P = .9). Trazodone and m-CPP achieved steady-state concentrations, with an accumulation ratio of 1.45 ± 0.2. CONCLUSIONS AND CLINICAL IMPORTANCE Although it did not affect recumbency, trazodone at 7.5 mg/kg q12h decreased step frequency by approximately 44%.
Collapse
Affiliation(s)
- Kallie Hobbs
- Department of Large Animal Clinical SciencesUniversity of Florida College of Veterinary MedicineGainesvilleFloridaUSA
| | - Daniela Luethy
- Department of Large Animal Clinical SciencesUniversity of Florida College of Veterinary MedicineGainesvilleFloridaUSA
| | - Jennifer Davis
- Department of Biomedical Sciences and PathobiologyVirginia‐Maryland College of Veterinary MedicineBlacksburgVirginiaUSA
| | - Martha Mallicote
- Department of Large Animal Clinical SciencesUniversity of Florida College of Veterinary MedicineGainesvilleFloridaUSA
| | - Catherine Torcivia
- Department of Clinical Studies‐New Bolton Center, School of Veterinary MedicineUniversity of PennsylvaniaKennett SquarePennsylvaniaUSA
| | - Jeaneen Kulp
- Department of Clinical Studies‐New Bolton Center, School of Veterinary MedicineUniversity of PennsylvaniaKennett SquarePennsylvaniaUSA
| | - Darko Stefanovski
- Department of Clinical Studies‐New Bolton Center, School of Veterinary MedicineUniversity of PennsylvaniaKennett SquarePennsylvaniaUSA
| | - Catherine Futterman
- Department of Large Animal Clinical SciencesUniversity of Florida College of Veterinary MedicineGainesvilleFloridaUSA
| | - Freya Cooper
- Department of Large Animal Clinical SciencesUniversity of Florida College of Veterinary MedicineGainesvilleFloridaUSA
| | - Andrew van Eps
- Department of Clinical Studies‐New Bolton Center, School of Veterinary MedicineUniversity of PennsylvaniaKennett SquarePennsylvaniaUSA
| |
Collapse
|
5
|
Marzok M, Kandeel M, Alkhodair K, Abdel-Raheem S, Ismail H, Farag A, Ibrahim H, El-Ashkar M, Shousha S, El-Khodery S. Evaluation of cardiac indices using M-mode echocardiography after administration of metoclopramide and ondansetron in donkeys ( Equus asinus): an experimental study. Front Vet Sci 2023; 10:1189710. [PMID: 37680391 PMCID: PMC10480612 DOI: 10.3389/fvets.2023.1189710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Accepted: 08/01/2023] [Indexed: 09/01/2023] Open
Abstract
The aim of the present study was to evaluate cardiac indices using M-mode echocardiography after the administration of metoclopramide and ondansetron in donkeys. For this purpose, 10 apparently healthy Egyptian Baladi donkeys (Equus asinus) were used in a crossover prospective study. Two trials were conducted with the administration of metoclopramide hydrochloride anhydrous at a dose of 0.25 mg Kg-1 and ondansetron hydrochloride sodium at a dose of 0.15 mg Kg-1. The control group (placebo) received a total volume of 50 mL of isotonic saline at 0.9%. An echocardiographic examination was performed using a Digital Color Doppler Ultrasound System equipped with a 2-3.9 MHz phased array sector scanner transducer. In general, the fractional shortening (FS%) was significantly affected by the time for metoclopramide (p = 0.031) and ondansetron (p = 0.047) compared with those of placebo, with treatment with metoclopramide provoking significantly higher percentages of FS% at T60 (p = 0.009) and T90 (p = 0.028) compared with those for ondansetron and placebo. The interaction of time x treatment also showed a statistically significant alteration of FS% (p < 0.05), while the values returned to the basal line at T240. Metoclopramide induced a significant decrease in E-point to septal separation (EPSS) at T90 (p = 0.005), and T240 (p = 0.007) compared with ondansetron and placebo. The time x treatment interaction also showed a significant (p < 0.05) variation in EPSS, with values returning to the basal line at T300. Mitral valve opening velocity (DE SLP) values were significantly affected by time (p = 0.004) in the metoclopramide group compared with those of ondansetron and placebo. Administration of metoclopramide and ondansetron provoked significant alterations of DE SLP at T60 (p = 0.039), T120 (p = 0.036), and T300 (p = 0.005) compared with placebo. In conclusion, caution should be exercised when administering both treatments, especially to animals with suspected cardiac problems.
Collapse
Affiliation(s)
- Mohamed Marzok
- Department of Clinical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
- Faculty of Veterinary Medicine, Department of Surgery, Kafrelsheikh University, Kafrelsheikh, Egypt
| | - Mahmoud Kandeel
- Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
- Faculty of Veterinary Medicine, Department of Pharmacology, Kafrelsheikh University, Kafrelsheikh, Egypt
| | - Khaled Alkhodair
- Department of Anatomy, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
| | - Sherief Abdel-Raheem
- Department of Public Health, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
- Faculty of Veterinary Medicine, Department of Animal Nutrition and Clinical Nutrition, Assiut University, Assiut, Egypt
| | - Hisham Ismail
- Faculty of Veterinary Medicine, Department of Animal Nutrition and Clinical Nutrition, Assiut University, Assiut, Egypt
- Faculty of Veterinary Medicine, Department of Food Hygiene "Meat Hygiene", Assiut University, Assiut, Egypt
| | - Alshimaa Farag
- Faculty of Veterinary Medicine, Department of Internal Medicine, Infectious Diseases and Fish Diseases, Mansoura University, Manosura, Egypt
| | - Hossam Ibrahim
- Faculty of Veterinary Medicine, Department of Internal Medicine, Infectious Diseases and Fish Diseases, Mansoura University, Manosura, Egypt
| | - Maged El-Ashkar
- Faculty of Veterinary Medicine, Department of Internal Medicine, Infectious Diseases and Fish Diseases, Mansoura University, Manosura, Egypt
| | - Saad Shousha
- Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
- Faculty of Veterinary Medicine, Department of Physiology, Benha University, Benha, Egypt
| | - Sabry El-Khodery
- Faculty of Veterinary Medicine, Department of Internal Medicine, Infectious Diseases and Fish Diseases, Mansoura University, Manosura, Egypt
| |
Collapse
|
6
|
EFFECTS OF A SINGLE ORAL DOSE OF TRAZODONE ON BEHAVIOR AND SERUM CORTISOL LEVELS IN BLUE WILDEBEEST ( CONNOCHAETES TAURINUS). J Zoo Wildl Med 2023; 53:679-688. [PMID: 36640069 DOI: 10.1638/2021-0145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/22/2022] [Indexed: 01/09/2023] Open
Abstract
Trazodone is a dose-dependent serotonin antagonist and agonist used to treat anxiety-related conditions. Trauma has been identified as the leading cause of morbidity and mortality in several nondomestic ruminant species and can be exacerbated by stress. In a recent study in domestic goats (Capra aegagrus hircus), trazodone reduced activity levels without adverse effects. Trazodone could allow for safer capture and handling in nondomestic ruminant species. The objectives of this study were to identify a dose of trazodone that decreases activity levels in captive blue wildebeest (Connochaetes taurinus) and to evaluate its safety and its effects on serum cortisol levels following a routine veterinary procedure. A pilot study using ethograms identified a group fed 15 mg/kg oral dose of trazodone as effective to reduce activity levels. Over 6 h, this dose resulted in a 111% increase in time spent sleeping or resting (P = 0.0003), a 41% increase in time spent lying down (P = 0.0016), a 64% reduction in time spent moving (P= 0.005), and a 65% reduction in time spent being vigilant (P= 0.026). Systemic absorption of trazodone was identified when plasma concentrations were measured after 2 h (95 ± 48 µg/L). Serum cortisol levels during a routine venipuncture event were not significantly different following trazodone administration (P > 0.05). Mild hyporexia was the only adverse effect noted at 15 mg/kg and was absent at a 12 mg/kg dose. Trazodone appears safe and promising to decrease activity in blue wildebeest and might thus have a positive effect on nondomestic ruminant welfare and the safety of veterinary procedures.
Collapse
|
7
|
Waitt Wolker LH, Veltri CA, Pearman K, Lozoya M, Norris JW. Pharmacokinetics of fluoxetine in horses following oral administration. J Vet Pharmacol Ther 2021; 45:63-68. [PMID: 34747024 DOI: 10.1111/jvp.13029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 05/03/2021] [Accepted: 10/22/2021] [Indexed: 12/01/2022]
Abstract
This study aimed to investigate pharmacokinetics of fluoxetine in horses and validate a method for liquid chromatography mass spectrometry analysis of serum levels. Fluoxetine pharmacokinetics were determined using 10 healthy, adult horses. Fluoxetine pharmacokinetics following a single oral dose (0.25 mg/kg) were determined using blood samples collected prior to and at several time points over 7 days following administration. Serum concentrations of fluoxetine and its bioactive metabolite norfluoxetine were measured using liquid chromatography coupled to an accurate mass/high-resolution mass spectrometer. Pharmacokinetic parameters were estimated using a noncompartmental model. Time to maximum serum concentration and serum half-life of fluoxetine was 1.5 and 15.6 h, respectively. Steady-state serum concentrations were evaluated using five horses each receiving fluoxetine (0.25 mg/kg, PO, q24hrs) for 8 weeks and were found to be 62.9 ± 25.5 ng/ml on average. Norfluoxetine was not detected in any sample.
Collapse
Affiliation(s)
- Laura H Waitt Wolker
- Department of Equine Medicine and Surgery, College of Veterinary Medicine, Midwestern University, Glendale, Arizona, USA
| | - Charles A Veltri
- Pharmaceutical Sciences Department, College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona, USA
| | - Krista Pearman
- Department of Pharmacology, College of Graduate Studies, Midwestern University, Glendale, Arizona, USA
| | - Maria Lozoya
- Pharmaceutical Sciences Department, College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona, USA
| | - Jeffrey W Norris
- Department of Pharmacology, College of Graduate Studies, Midwestern University, Glendale, Arizona, USA
| |
Collapse
|
8
|
PHARMACOKINETICS AND CLINICAL EFFECTS OF A SINGLE ORAL DOSE OF TRAZODONE IN THE DOMESTIC GOAT ( CAPRA HIRCUS) AS A MODEL FOR WILD RUMINANTS. J Zoo Wildl Med 2021; 51:896-904. [PMID: 33480570 DOI: 10.1638/2019-0242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/24/2020] [Indexed: 11/21/2022] Open
Abstract
Trazodone is an antianxiety medication commonly used in human and veterinary medicine. Stress-related trauma is the leading cause of morbidity and mortality in wild ruminant species. Trazodone could reduce stress and allow safer capture and handling, thus having a positive effect on their welfare. The objective of this study was to describe the clinical effects and pharmacokinetic profile of an oral dose of trazodone in domestic goats (Capra hircus) as a model for wild ruminants. A pilot study using ethograms and accelerometers identified an oral dose of 10 mg/kg as optimal to reduce activity levels. This dose resulted in a 502% increase in time spent sleeping (P=0.0016) and a 623% increase in time spent lying down (P=0.01). Additionally, there were reductions of 72% in time spent grooming (P=0.02), 49% in time spent moving (P=0.01), and 87% in time spent observing (P=0.0002). Activity levels were significantly decreased by 31% for 4 hr following administration (P=0.049). There were no observed adverse effects. Time spent eating or ruminating was not affected by trazodone administration (P > 0.05). The pharmacokinetics of trazodone following a single oral dose of 10 mg/kg in 7 goats was assessed. All animals achieved plasma concentrations over 130 ng/ml, a level considered therapeutic in humans and dogs, for a mean of 6.4 ± 5.0 hr. Mean terminal half-life was 10.55 ± 6.80 hr. All goats achieved maximum concentration within 5-15 min and still had detectable plasma levels at 24 hr. Trazodone appears promising to decrease stress in exotic ruminant species. Further research is warranted to establish its efficacy in other ruminant species and clinical situations.
Collapse
|
9
|
Moss AL, Hritz RL, Hector RC, Wotman KL. Investigation of the effects of orally administered trazodone on intraocular pressure, pupil diameter, physical examination variables, and sedation level in healthy equids. Am J Vet Res 2021; 82:138-143. [PMID: 33480276 DOI: 10.2460/ajvr.82.2.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To investigate the effects of orally administered trazodone on intraocular pressure (IOP), pupil diameter measured in the vertical plane (ie, vertical pupil diameter [VPD]), selected physical examination variables, and sedation level in healthy equids. ANIMALS 7 horses and 1 pony. PROCEDURES Food was withheld for 12 hours prior to drug administration. After baseline (time 0) sedation scoring, physical examination, and measurement of IOP and VPD, equids received 1 dose (approx 6 mg/kg) of trazodone orally. Examination and measurement procedures were repeated 0.5, 1, 2, 4, 8, 12, and 24 hours after drug administration. Blood samples were collected at each time point for analysis of plasma trazodone concentrations. Repeated-measures analysis was used to compare examination results between downstream time points and baseline. RESULTS 7 of 8 equids had mild sedation from 0.5 to 8 hours after treatment; compared with baseline values, mean IOP was significantly lower from 0.5 hours to 8 hours, mean VPD was significantly smaller at 0.5 hours, and mean rectal temperature was significantly lower from 1 to 8 hours after drug administration. Adverse effects (signs of excitement in 1 equid and sweating in 4) were self-limiting and considered minor. Mean maximum plasma concentration of trazodone was 1,493 ng/mL 0.75 hours after administration, and terminal half-life of the drug was 9.96 hours. CONCLUSIONS AND CLINICAL RELEVANCE The described oral dose of trazadone elicited sedation with a few self-limiting adverse effects in the study sample. Drug effects on IOP and VPD may alter ocular examination findings. Further investigation is warranted prior to use of trazodone for sedation in equids, particularly those with ophthalmic conditions.
Collapse
|
10
|
Fontenot RL, Mochal-King CA, Sprinkle SB, Wills RW, Calder CD. Retrospective Evaluation of Fluoxetine Hydrochloride Use in Horses: 95 Cases (2010-2019). J Equine Vet Sci 2020; 97:103340. [PMID: 33478760 DOI: 10.1016/j.jevs.2020.103340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/20/2020] [Accepted: 11/20/2020] [Indexed: 11/24/2022]
Abstract
This study aimed to describe the clinical use of oral fluoxetine hydrochloride administration in horses using a retrospective medical records analysis and to determine owner perception of efficacy via a standardized questionnaire. The records of ninety-five horses for which fluoxetine had been prescribed by the equine service of a veterinary teaching hospital from November 2010 and February 2019 were identified, and data were collected from the medical records. A standardized questionnaire was used to obtain data from owners regarding length of administration, ease of administration, adverse effects, and whether the owner noted improvement in the horse's behavior. Ninety-five horses received fluoxetine during the study period. Fluoxetine was prescribed to facilitate stall rest in 68 horses (Group A) and for behavior-related problems in 27 horses (Group B). The mean dosage was 0.25 mg/kg (range 0.15-0.54). Forty-seven of the 66 owners (71%) that completed the follow-up questionnaire reported a perceived improvement in the animal's behavior (29/41 in Group A and 18/25 in Group B). Fifty-eight owners (88%) reported that they felt the medication was easy to administer. When used to facilitate extended stall confinement, fluoxetine appears to be perceived as efficacious by most owners. Although the number of behavioral cases was low, the results indicate that the drug may also be useful for some problem behaviors. Further controlled behavioral studies are needed to investigate the use of fluoxetine for equine behavioral problems.
Collapse
Affiliation(s)
- Robin L Fontenot
- Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS.
| | - Cathleen A Mochal-King
- Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS
| | - Saybl B Sprinkle
- Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS
| | - Robert W Wills
- The Department of Comparative Biomedical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS
| | - Christine D Calder
- Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS
| |
Collapse
|
11
|
Wong ASY, Choi TLS, Kwok KY, Wong JKY, Wan TSM, Ho ENM. Doping control analysis of antipsychotics and other prohibited substances in equine plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1147:122132. [PMID: 32417678 DOI: 10.1016/j.jchromb.2020.122132] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 04/26/2020] [Accepted: 04/27/2020] [Indexed: 01/06/2023]
Abstract
Antipsychotics are banned substances and considered by the Fédération Equestrian Internationale (FEI) to have no legitimate use in equine medicine and/or have a high potential for abuse. These substances are also prohibited in horseracing according to Article 6 of the International Agreement on Breeding, Racing and Wagering (published by the International Federation of Horseracing Authorities). Over the years, antipsychotics have been abused or misused in equestrian sports and horseracing. A recent review of literature shows that there is yet a comprehensive screening method for antipsychotics in equine samples. This paper describes an efficient liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the simultaneous detection of over 80 antipsychotics and other prohibited substances at sub-parts-per-billion (ppb) to low-ppb levels in equine plasma after solid-phase extraction (SPE).
Collapse
Affiliation(s)
- April S Y Wong
- Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China.
| | - Timmy L S Choi
- Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China
| | - Karen Y Kwok
- Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China
| | - Jenny K Y Wong
- Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China
| | - Terence S M Wan
- Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China
| | - Emmie N M Ho
- Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China.
| |
Collapse
|
12
|
Carroll SL, Sykes BW, Mills PC. An online survey investigating perceived prevalence and treatment options for stereotypic behaviours in horses and undesirable behaviours associated with handling and riding. EQUINE VET EDUC 2020. [DOI: 10.1111/eve.13250] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- S. L. Carroll
- School of Veterinary Science University of Queensland Gatton Queensland Australia
| | - B. W. Sykes
- School of Veterinary Science University of Queensland Gatton Queensland Australia
| | - P. C. Mills
- School of Veterinary Science University of Queensland Gatton Queensland Australia
| |
Collapse
|
13
|
Davis JL, Schirmer J, Medlin E. Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse. J Vet Pharmacol Ther 2018; 41:393-401. [PMID: 29333613 PMCID: PMC7167085 DOI: 10.1111/jvp.12477] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 12/01/2017] [Indexed: 11/28/2022]
Abstract
Trazodone is a serotonin receptor antagonist and reuptake inhibitor used extensively as an anxiolytic in human and small animal veterinary medicine. The aims of this study were to determine the pharmacokinetics of oral trazodone in experimental horses and to evaluate the effect of oral trazodone in clinical horses. Six experimental horses were administered trazodone at 7.5 or 10 mg/kg. Plasma concentrations of trazodone and its metabolite (m-CPP) were determined via UPLC-MS/MS. Noncompartmental pharmacokinetic analysis, sedation and ataxia scores were determined. Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 μg/ml and half-life of the terminal phase of approximately 7 hr. The metabolite was present at low levels in all horses, representing only 2.5% of the total area under the curve. In experimental horses, concentration-dependent sedation and ataxia were noted, lasting up to 12 hr. For clinical cases, medical records of horses treated with trazodone for various abnormal behaviours were reviewed and data were summarized. Trazodone was successful in modifying behavioural problems to some degree in 17 of 18 clinical cases. Tolerance and subsequent lack of drug effect occurred in two of 18 clinical cases following 14 or 21 days of use. In both populations of horses, adverse effects attributed to trazodone include oversedation, muscle fasciculations and transient arrhythmias.
Collapse
Affiliation(s)
- J. L. Davis
- VA‐MD College of Veterinary MedicineBlacksburgVAUSA
| | - J. Schirmer
- North Carolina State University College of Veterinary MedicineRaleighNCUSA
| | - E. Medlin
- North Carolina State University College of Veterinary MedicineRaleighNCUSA
| |
Collapse
|